Importance

Carotid endarterectomy is associated with lower risk of perioperative stroke compared to transfemoral carotid artery stenting in the treatment of carotid artery stenosis. However, there is discrepancy in data regarding long-term outcomes. We aimed to compare long-term outcomes of carotid endarterectomy vs transfemoral carotid artery stenting using the Medicare-matched Vascular Quality Initiative Vascular Implant Surveillance and Interventional Outcomes Network database.

Methods

We assessed patients undergoing first-time carotid endarterectomy or transfemoral carotid artery stenting in VQI-VISION from January 2003 to December 2018. Patients with prior history of carotid revascularization, non-transfemoral stenting, stenting performed without distal embolic protection, multiple or non-atherosclerotic lesions, or concomitant procedures were excluded. The primary outcome of interest was all-cause mortality, any stroke, and combined endpoint of death or stroke. We additionally performed propensity score matching and stratification based on symptomatic status.

Results

A total of 80,146 carotid revascularizations were performed of which 72,615 were carotid endarterectomy and 7,531 were transfemoral carotid artery stenting. CEA was associated with significantly lower risk of death (57.8% vs. 70.4%, aHR 0.46, 95%CI 0.41-0.52, p<0.001), stroke (21.3% vs. 26.6%, aHR 0.63, 95%CI 0.57-0.69, p<0.001) and combined endpoint of death and stroke (65.3% vs. 76.5%, HR 0.49, 95%CI:0.44-0.55, p<0.001) at 10 years. These findings were reflected in the propensity-matched cohort (combined endpoint: 34.6% vs. 46.8%, HR 0.53, 95%CI: 0.46-0.62) at 4 years as well as stratified analyses of combined endpoint by symptomatic status (asymptomatic: 63.2% vs. 74.9%, HR 0.49, 95%CI: 0.43-0.58, p<0.001; symptomatic 69.9% vs. 78.3%, HR 0.51, 95%CI: 0.45-0.59, p<0.001) at 10 years.

Conclusions

In this analysis of North American real-world data, CEA was associated with greater long-term survival and fewer strokes compared to TFCAS. These findings support the continued use of CEA as the first-line revascularization procedure.

Objective

Blood pressure fluctuations are a common hemodynamic alteration following carotid artery stenting either with transfemoral (TFCAS) or transcarotid (TCAR) approach and are thought to be related to alteration in baroreceptor function due to angioplasty and stent expansion. These fluctuations are particularly worrisome in the high-risk patient population referred for CAS. This study aims to evaluate the outcomes of patients who required the administration of intravenous blood pressure medication (IVBPmed) for hypotension or hypertension after CAS.

Methods

All patients undergoing carotid revascularization in the Vascular Quality Initiative (VQI) database between 2016 and 2021 were included. We compared outcomes of patients who required postoperative IVBPmed to treat hyper- or hypotension with normotensive patients. In-hospital outcomes were compared using multivariable logistic regression. One-year outcomes were assessed using Kaplan-Meier survival and multivariable Cox proportional hazard regression analyses.

Results

We identified 38,510 patients undergoing CAS (57.7% TCAR and 42.3% TFCAS), of which, 30% received IVBPmed for treatment of either postoperative hypertension (12.6%) or hypotension (16.4%). In multivariable analysis, postoperative hypotension was associated with a higher risk of stroke, death, or myocardial infarction (MI) (odds ratio [OR], 3.1; 95% confidence interval [CI], 2.6-3.6; P < .001), stroke or death (OR, 2.9; 95% CI, 2.4-3.5; P < .001), stroke (OR, 2.6; 95% CI, 2.1-3.2; P < .001), death (OR, 3.5; 95% CI, 2.6-4.8; P < .001), MI (OR, 4.7; 95% CI, 3.3-6.7; P < .001), and bleeding (OR, 1.96; 95% CI, 1.4-2.7; P < .001) compared with normotensive patients. Postoperative hypertension was associated with a higher risk of stroke, death, or MI (OR, 3.6; 95% CI, 3-4.4; P < .001), stroke or death (OR, 3.3; 95% CI, 2.7-4.1; P < .001), stroke (OR, 3.7; 95% CI, 3-4.7; P < .001), death (OR, 2.7; 95% CI, 1.9-3.9; P < .001), MI (OR, 5.7; 95% CI, 3.9-8.3; P < .001), and bleeding (OR, 1.9; 95% CI, 1.4-2.7; P < .001) compared with normotensive patients.

Conclusions

Postoperative hypertension or hypotension requiring IVBPmed after CAS is associated with an increased risk of in-hospital stroke, death, MI, and bleeding. Postoperative hypertension is associated with worse survival at 1 year. This study indicates that the need for IVBPmed after CAS is not benign; therefore, these patients necessitate aggressive perioperative medical management and safe techniques to avoid hypo and hypertension. Close follow-up and continue medical management are needed to maximize these patients' survival.